Search results for "Lute"

showing 10 items of 1384 documents

Inverse correlation between baseline inhibin B and FSH after stimulation with GnRH: a study of serum levels of inhibin A and B, pro alpha-C and activ…

2000

OBJECTIVE: Interest has focused recently on the influences of the polypeptide factors inhibin and activin on the selective regulation of the pituitary secretion of gonadotropins. DESIGN: Measurement of the concentrations of inhibin-related proteins in relation to the changes in pituitary gonadotropin (FSH, LH) parameters, after GnRH stimulation with a bolus injection of 100 microg gonadorelin, in 19 women with ovulatory disturbances. METHODS: Serum levels of inhibin A and B, activin A, and pro alpha-C were measured using sensitive ELISA kits. RESULTS: Within 60 min after GnRH stimulation, FSH values doubled from 5 to 10 mU/ml (P < 0.001). LH increased 12-fold from 2 to 24 mU/ml (P < 0…

Adultendocrine systemmedicine.medical_specialtyInhibin aAdolescentmedicine.drug_classEndocrinology Diabetes and MetabolismAlpha (ethology)StimulationGonadotropin-releasing hormoneGonadotropin-Releasing HormoneFollicle-stimulating hormoneEndocrinologyInternal medicinemedicineHumansInhibinsOvarian DiseasesAmenorrheaEstradiolChemistryHypogonadismGeneral MedicineLuteinizing HormoneActivinsEndocrinologyAmenorrheaFemaleGonadotropinmedicine.symptomFollicle Stimulating HormoneLuteinizing hormonehormones hormone substitutes and hormone antagonistsHypothalamic DiseasesEuropean journal of endocrinology
researchProduct

Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vi…

2007

Objective: To investigate the effects of recombinant (r-) LH supplementation in “low responder” patients undergoing ovarian stimulation with r-FSH for an IVF program. The apoptosis rate in cumulus cells was used as an indicator of oocyte quality. Design: Comparison of the rate of DNA fragmentation and caspase-3 activity in cumulus cells in women stimulated with r-LH and r-FSH, versus patients treated with r-FSH alone (control). Setting: In vitro fertilization (IVF) laboratory. Patient(s): Forty patients undergoing assisted fertilization programs treated with a GnRH agonist, or r-FSH treatment begun on day 3 of the cycle (control). In the r-LH group, from day 8 of gonadotropin stimulation, 1…

Adultendocrine systemmedicine.medical_specialtyPregnancy Ratemedicine.drug_classmedicine.medical_treatmentOvaryApoptosisDNA FragmentationFertilization in VitroBiologyOvulation InductionPregnancyInternal medicinemedicineIn Situ Nick-End LabelingHumansrecombinant LHOvarian follicleimplantation rateHuman cumulus cells; apoptosis; IVF; pregnancy rate; implantation rate; recombinant LH; oocyte qualityIn vitro fertilisationGranulosa CellsCaspase 3Obstetrics and GynecologyLuteinizing HormoneOocyteCumulus oophorusapoptosiRecombinant ProteinsPregnancy ratemedicine.anatomical_structureEndocrinologyHuman cumulus cellReproductive MedicineIVFFemaleoocyte qualityGonadotropinFollicle Stimulating HormoneLuteinizing hormonehormones hormone substitutes and hormone antagonistsFertility and sterility
researchProduct

High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist.

2011

High daily doses of gonadotrophin-releasing hormone (GnRH) antagonists during the follicular phase of ovarian stimulation were associated with low implantation rates. To test if this occurred because of profound pituitary suppression, the pituitary response was suppressed with a high-dose GnRH antagonist and recombinant LH (rLH) was added back to correct the implantation rate. An open-label, randomized, controlled, prospective clinical study in 60 patients undergoing IVF was performed. GnRH antagonist was initiated on day 6 of stimulation (2 mg/day) together with 375 IU rLH, and maintained until the day of HCG administration. Controls received 0.25 mg/day GnRH antagonist. Fluctuating LH con…

Adultendocrine systemmedicine.medical_specialtymedicine.medical_treatmentStimulationlaw.inventionGonadotropin-Releasing HormoneOvulation InductionlawInternal medicineFollicular phaseMedicineHumansProspective StudiesAdverse effectProspective cohort studyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyLuteinizing HormoneRecombinant ProteinsDose–response relationshipEndocrinologyReproductive MedicineRecombinant DNAOvulation inductionFemalebusinesshormones hormone substitutes and hormone antagonistsDevelopmental BiologyHormoneReproductive biomedicine online
researchProduct

Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin-like growth factor binding protein-3 to octreotide in polycystic ova…

1995

Objective To determine if the somatostatin analog, octreotide, affects insulin and related peptides and, hence, androgen levels differently between polycystic ovary syndrome (PCOS) patients and controls. Design Prospective controlled trial. Setting Reproductive endocrinology clinic of our medical center. Patients Eleven women with PCOS and six matched ovulatory controls. Interventions Octreotide (100 μg) was administered subcutaneously in the midfollicular phase. Serum was obtained before and at 60, 120, 180, and 240 minutes after octreotide. Main Outcome Measures Fasting insulin, insulin-like growth factor 1 (IGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), T, androstenedion…

Adultmedicine.medical_specialtyAdolescentendocrine system diseasesmedicine.drug_classmedicine.medical_treatmentOctreotideBiologyOctreotideInsulin-like growth factor-binding proteinInternal medicinemedicineHumansInsulinTestosteroneProspective StudiesInsulin-Like Growth Factor ITestosteronePancreatic hormoneInsulinAndrostenedioneObstetrics and GynecologyFastingLuteinizing HormoneAndrogenPolycystic ovaryInsulin-Like Growth Factor Binding ProteinsSomatostatinEndocrinologyReproductive Medicinebiology.proteinFemaleCarrier ProteinsPolycystic Ovary Syndromemedicine.drugFertility and Sterility
researchProduct

Macular edema computer-aided evaluation in ocular vein occlusions.

1998

This paper is concerned with the use of digital fundus imaging to detect, quantify, and follow up macular angiographic leakage due to retinal vein occlusions. Images were matched automatically. We detected those pixels with a high increment in gray level within the closest area to the foveal center. Binary images displaying leakage were obtained. The procedure was checked against two observers' agreement. Twenty-one angiographic studies were collected. Two images of each sequence were selected for digitalization. Numerical descriptors of the leakage were proposed and quantification plots were designed for each pair of images. Interobserver concordance ranged between 82 and 98% when manually…

Adultmedicine.medical_specialtyComputingMethodologies_IMAGEPROCESSINGANDCOMPUTERVISIONMedicine (miscellaneous)Capillary PermeabilityFovealOcclusionRetinal Vein OcclusionmedicineEdemaHumansMacula LuteaDiagnosis Computer-AssistedFluorescein AngiographyMacular edemaObserver VariationPixelmedicine.diagnostic_testbusiness.industryBinary imagemedicine.diseaseFluorescein angiographyPrognosisEvaluation Studies as TopicMaculopathyFemaleRadiologybusinessRetinopathyComputers and biomedical research, an international journal
researchProduct

Hypogonadism and Hormone Replacement Therapy on Bone Mass of Adult Women with Thalassemia Major

2002

We studied bone mass and metabolism in 30 adult women (age 28.5 +/- 1.3) with thalassemia major (TM) and evaluated whether prolonged hormone replacement therapy (HRT) was able to optimize bone accrual. TM patients had reduced bone mass, increased bone turnover and lower serum gonadotropin and estradiol levels compared with 10 normal women of similar age. A significant correlation was found between bone mass and sex hormone levels. Six TM patients with normal ovarian function had normal bone turnover markers and modestly low bone mass (lumbar spine -1.29 +/- 0.31; femoral neck -0.60+/-0.21; Z-score). The other 24 TM women were hypogonadic and had significantly lower bone mass for age (lumbar…

Adultmedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and MetabolismThalassemiaOsteoporosisBone remodelingAdult womenEndocrinologySex hormone-binding globulinBone DensityInternal medicinemedicineHumansOrthopedics and Sports MedicineFemoral neckEstradiolbiologybusiness.industryHypogonadismbeta-ThalassemiaOsteoporosiLuteinizing Hormonemedicine.diseaseThalassaemiaEndocrinologymedicine.anatomical_structureTransgender hormone therapyOrthopedic surgerybiology.proteinFemaleFollicle Stimulating HormonebusinessCalcified Tissue International
researchProduct

Report on a very young dizygotic human twin pregnancy.

1981

Two ova implanted in one uterus were found at the autopsy of a 28-year-old woman. The ovulation age of both implantations has been estimated to be 10–12 days. The presence of two equally large corpora lutea, one in each ovary, indicates that the implanted ova originated from different ovaries. Thus, an “ovulatio biovarialis” seems to be the basis for the dizygotic twinning in this case. The case is believed to be the only documented example of a very early dizygotic, fraternal pregnancy in humans.

Adultmedicine.medical_specialtyInjury controlmedia_common.quotation_subjectUterusTwinsPoison controlAutopsyOvaryGestational AgeCorpus LuteumPregnancymedicineTwins DizygoticHumansOvulationTwin Pregnancymedia_commonGynecologyPregnancybusiness.industryOvaryObstetrics and GynecologyGeneral Medicinemedicine.diseaseSuicidemedicine.anatomical_structureFemalebusinessArchives of gynecology
researchProduct

Pancreatitis-associated protein in patients with celiac disease: Serum levels and immunocytochemical localization in small intestine

1997

Since PAP is a stress protein expressed in human pancreas during pancreatitis but also constitutively synthesized in the small intestine, we looked whether its expression would be altered in patients with celiac disease. Serum PAP concentrations were determined consecutively in 54 patients with celiac disease on a free diet (group A), in 47 patients with celiac disease on a gluten-free diet (group B), in 22 patients with other intestinal pathologies but with normal intestinal mucosa (group C), in 14 patients with retarded growth, no gastrointestinal disease and normal intestinal mucosa (group D), and in 17 controls (group E). Serum PAP levels (ng/ml) were significantly higher in group A (12…

Adultmedicine.medical_specialtyPathologyGlutensBiopsyImmunocytochemistryPancreatitis-Associated ProteinsBiologyGastroenterologyCoeliac diseaseJejunumIntestinal mucosaAntigens NeoplasmLectinsInternal medicineIntestine SmallBiomarkers TumormedicineAnimalsHumansLectins C-TypeIntestinal MucosaPancreatitis-Associated ProteinsChildGastroenterologyAcute-phase proteinInfantmedicine.diseaseImmunohistochemistrySmall intestineImmunoglobulin ACeliac DiseaseJejunummedicine.anatomical_structureChild PreschoolImmunoglobulin GPancreatitisFemaleRabbitsAcute-Phase Proteins
researchProduct

Analysis of serum and endometrial progesterone in determining endometrial receptivity.

2021

Abstract STUDY QUESTION Is there a relationship between serum and endometrial progesterone (P4) levels, including P4 and metabolites (oestrone, oestradiol and 17α-hydroxyprogesterone), and endometrial receptivity? SUMMARY ANSWER Serum P4 levels were not correlated with endometrial P4, nor associated with endometrial receptivity as determined by the ERA® test; however, endometrial P4 and 17α-hydroxyprogesterone levels were positively correlated and related to endometrial receptivity by ERA. WHAT IS KNOWN ALREADY Acquisition of endometrial receptivity is governed by P4, which induces secretory transformation. A close relationship between serum P4 and pregnancy outcome is reported for hormone …

Adultmedicine.medical_specialtyPregnancy Ratemedicine.medical_treatmentPopulationUterusLuteal phaseEndometriumEndometriumPregnancyMedicine17a-hydroxyprogesterone ERA test P4 endometrial receptivity progesterone steroid hormones metabolitesHumansEmbryo ImplantationProspective StudieseducationProspective cohort studyProgesteroneGynecologyeducation.field_of_studyPregnancymedicine.diagnostic_testbusiness.industryRehabilitationObstetrics and GynecologyHormone replacement therapy (menopause)medicine.diseaseEmbryo Transfermedicine.anatomical_structureReproductive MedicineFemalebusinesshormones hormone substitutes and hormone antagonistsEndometrial biopsyHuman reproduction (Oxford, England)
researchProduct

Gynecological Disorders in Patients with Non-celiac Wheat Sensitivity

2019

Background: Non-celiac wheat sensitivity (NCWS) most frequently presents clinically with irritable bowel syndrome (IBS)-like symptoms, although many extra-intestinal manifestations have also been attributed to it. No studies to date have evaluated the presence and frequency of gynecological symptoms in NCWS. Aim: To evaluate the frequency of gynecological disorders in patients with NCWS. Patients and Methods: Sixty-eight women with NCWS were included in the study. A questionnaire investigating gynecological symptoms and recurrent cystitis was administered, and patients reporting symptoms were then examined by specialists. Three control groups were selected: 52 patients with IBS not related …

Adultmedicine.medical_specialtySettore MED/09 - Medicina InternaPhysiologyNon-celiac wheat sensitivitymedia_common.quotation_subjectCystitiDiseaseWheat HypersensitivityGastroenterology03 medical and health sciencesDiet Gluten-FreeYoung Adult0302 clinical medicineInternal medicineCystitismedicineHumansIn patientGynecological disordersProspective StudiesVaginitisIrritable bowel syndromeMenstrual cycleVaginitismedia_commonbusiness.industryMenstrual cycle abnormalitieGastroenterologyHepatologyMiddle Agedmedicine.diseaseCeliac DiseaseIrritable bowel syndrome030220 oncology & carcinogenesisRecurrent cystitis030211 gastroenterology & hepatologyFemaleObstetric diseasebusinessFollow-Up Studies
researchProduct